Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis [0.03%]
TAS-102后继乐瑞atinib或相反顺序治疗转移性结直肠癌晚期患者的疗效和安全性：系统评价和Meta分析
Bannawich Sapapsap,Sirapratch Champarhorm,Anchana Pongpun et al.
Bannawich Sapapsap et al.
Background: Trifluridine/tipiracil (TAS-102) and regorafenib are approved and widely utilized as later-line treatment options for patients with metastatic colorectal cancer (mCRC). However, the optimal sequence between th...
Meta-Analysis
Chinese clinical oncology. 2026 Jun;15(3):42. DOI:10.21037/cco-2026-1-0018 2026
Rujia Zheng,Qitai Chen,Mengting Zhang et al.
Rujia Zheng et al.
Background: Sijunzi decoction (SJZD) is a traditional Chinese medicine (TCM) commonly used for pancreatic ductal adenocarcinoma (PDAC), but its mechanisms remain unclear. This study investigates its molecular basis using ...
Toxicity management in thoracic chemoradioimmunotherapy: pirfenidone for low grade pneumonitis and lung fibrosis [0.03%]
胸部放化疗免疫治疗的毒性管理：吡非尼酮用于低级别肺炎和肺纤维化
Franz Zehentmayr,Elvis Ruznic,Raphaela Moosbrugger et al.
Franz Zehentmayr et al.
Logan Shaver,Omer Jamy
Logan Shaver
Can recurrence-free survival replace overall survival for resectable esophageal cancer? [0.03%]
可切除性食管癌的无复发生存期能替代总生存期吗？
Jane E Rogers,Jaffer A Ajani
Jane E Rogers
Clonal hematopoiesis in breast cancer: moving beyond prevalence toward clinical relevance [0.03%]
乳腺癌中的克隆性血源造血现象：超越发生率，探讨其临床意义
Farah Shah,Catherine C Coombs
Farah Shah
Back to the future: "7+3" joins the venetoclax plus intensive chemotherapy movement [0.03%]
重返未来：“7+3”方案加入维奈克拉联合大强度化疗阵营
Michael Canonico,Somedeb Ball
Michael Canonico
Emine Hatipoglu,Robin L Jones
Emine Hatipoglu